RxDoctor Payments Data

Leigh Massey, MD

Gynecology · Wheeling, WVNPI 1780685727

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.3% of the total across 33 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations.

$732in general payments, 2019–2025

Across 33 payments — averaging $22.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$114
  • Amgen$97
  • Hologic Sales And Service, LLC$83
  • Exeltis, USA Inc.$75
  • Mayne Pharma Commercial LLC$45
  • Therapeuticsmd, Inc.$43
  • plus $275 from 11 others

What the payments were for

  • Food & beverage$69194%
  • Education$426%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few gynecology providers in West Virginiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$35,427
Medicare patients
365
Services billed
640

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron43$25,510
Estradiol155$15,180
YuvafemEstradiol11$2,247
Calcitonin-SalmonCalcitonin,salmon,synthetic16$1,718
Clobetasol Propionate62$1,435
Estradiol (Once Weekly)Estradiol14$1,352
Raloxifene Hcl36$1,287
Oxybutynin Chloride49$1,115
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip50$1,034
Oxybutynin Chloride ErOxybutynin Chloride25$912
Betamethasone Dipropionate18$873
ValacyclovirValacyclovir Hcl31$838
Fesoterodine Fumarate ErFesoterodine Fumarate15$810
Ibandronate Sodium17$538
Nystatin35$507

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$42$25,51043 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few gynecology providers in West Virginiaon file to place this against a meaningful peer group, so we don't.

Other gynecology in Wheeling

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →